
Publication
Government of Alberta launches nuclear energy engagement
On August 25, 2025, the Government of Alberta publicly re-affirmed its interest in nuclear energy with the launch of its Nuclear Energy Engagement (the Engagement).
Author:
Canada | Publication | March 26, 2020 - 7 PM ET
Based on the government announcements:
Workers
Workers must be at least 15 years of age, a resident in Canada and, for 2019 or in the 12-month period preceding their application, have a total income of at least $5,000 (or any other amount determined by regulation) from:
Eligibility
To be eligible, workers must:
1. Have involuntarily ceased to carry on their employment for reasons related to COVID-19 for at least 14 consecutive days including in the period of four weeks for which they are applying for CERB; and
2. Not receive, during that period:
CERB application
The application procedure, including its formalities, will be determined by regulation. The application may cover any period of four weeks included between March 15, 2020, and October 3, 2020. No CERB application may be submitted after December 2, 2020.
Amounts and duration of CERB
The amount of CERB to which the eligible worker is entitled for one given week will be determined by regulation, as it is not specified in the Act. Furthermore, the regulation could treat various categories of workers differently. In all cases, the CERB may be paid only up to 16 weeks or for the number of weeks to be determined by regulation.
Record of employment
The employer must produce a record of employment each time there is an interruption of earnings for one of its employees. Such an interruption of earnings occurs when employees:
Publication
On August 25, 2025, the Government of Alberta publicly re-affirmed its interest in nuclear energy with the launch of its Nuclear Energy Engagement (the Engagement).
Publication
Health Canada has proposed a major change to the regulation of biosimilar drugs that may accelerate biologic patent litigation in Canada. Following the lead of other jurisdictions, Health Canada has proposed that biosimilar manufacturers no longer be required to conduct phase 3 clinical trials to enter the Canadian market.
Subscribe and stay up to date with the latest legal news, information and events . . .
© Norton Rose Fulbright LLP 2025